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waiting for kidneys [2]. I did not suggest support of
kidney auctions. At present it is in fact illegal to buy and
sell organs in this country.
I also compared the recent attempts at electronic or- Cohort study of the treatmentgan commerce to historical Third World organ com-
merce, as reported by Chugh and Jha [3]. I predict that of severe HIV-associatedallowing a market to operate without regulation would
result, like it did in India, in a reverse “Robin Hood” nephropathy withphenomenon where organs are essentially stolen from
the poor and given to the rich. corticosteroidsThere are ways to tie financial incentives to organ
donation while remaining close to the spirit of donation To the Editor: We read the article in a recent issue
and preserving fair allocation, including death benefits of Kidney International by Eustace et al with great inter-
(like estate tax deductions or funeral expense reimburse- est [1]. The authors reported 18 episodes of infection
ment) and prospective sale, also called “donor insur- in a corticosteroid-treated group of patients with HIV-
ance” or a “futures market” whereby direct payment is associated nephropathy (HIVAN) the majority of which
made to beneficiaries upon death and subsequent har- were life-threatening, compared to 8 such episodes in the
vest. Only about one third of the 10,000 to 12,000 poten- non-corticosteroid–treated group. Despite these results,
tial cadaveric donors per year donate organs [4]. The the authors suggested that the therapy with corticoste-
remaining constitute an excellent resource for bridging roids is relatively safe. They based their conclusion on the
the gap between supply and demand. presumption that if non-corticosteroid–treated patients
The data presented by Gjertson and Cecka clearly were followed up for a similar length of time as the
show that living unrelated donor kidney transplantation corticosteroid-treated patients, the incidence of infec-
has a superior outcome to cadaveric donation [5]. This tions would be the same in both groups. However, this
makes paid living donation or a free market for organ may not be true in the era of highly active antiretroviral
transplantation particularly seductive. Sombolos and therapy (HAART), which has dramatically improved
survival of HIV-infected hemodialysis patients [2]. When
a clinician reaches a crossroad in treating patients with
HIVAN who are progressing toward end-stage renal dis-Ó 2001 by the International Society of Nephrology
